China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · Real-Time Price · USD
2.090
+0.010 (0.48%)
At close: Apr 28, 2026, 4:00 PM EDT
2.050
-0.040 (-1.91%)
Pre-market: Apr 29, 2026, 4:33 AM EDT
China SXT Pharmaceuticals Revenue
China SXT Pharmaceuticals had revenue of $626.57K in the half year ending September 30, 2025, a decrease of -33.31%. This brings the company's revenue in the last twelve months to $1.54M, down -15.42% year-over-year. In the fiscal year ending March 31, 2025, China SXT Pharmaceuticals had annual revenue of $1.74M, down -9.73%.
Revenue (ttm)
$1.54M
Revenue Growth
-15.42%
P/S Ratio
4.02
Revenue / Employee
$20,506
Employees
75
Market Cap
6.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.74M | -187.59K | -9.73% |
| Mar 31, 2024 | 1.93M | -43.18K | -2.19% |
| Mar 31, 2023 | 1.97M | -630.60K | -24.23% |
| Mar 31, 2022 | 2.60M | -2.18M | -45.53% |
| Mar 31, 2021 | 4.78M | -384.70K | -7.45% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biofrontera | 41.71M |
| Sunshine Biopharma | 36.31M |
| cbdMD | 19.09M |
| Sonoma Pharmaceuticals | 17.72M |
| RedHill Biopharma | 9.55M |
| InMed Pharmaceuticals | 4.51M |
| Akanda | 836.66K |
| Gelteq | 270.85K |
SXTC News
- 5 weeks ago - China SXT Pharmaceuticals, Inc. Announces Share Re-classification - GlobeNewsWire
- 3 months ago - China SXT Pharmaceuticals, Inc. Announces Share Consolidation - GlobeNewsWire
- 3 months ago - Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) - GlobeNewsWire
- 3 months ago - China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering - GlobeNewsWire
- 1 year ago - China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency - GlobeNewsWire
- 1 year ago - China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split - GlobeNewsWire